[ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE

Angelo Baldassare Cefalu', Antonio Carroccio, Lidia Di Prima, Giuseppe Ambrosiano, Lidia Di Prima, Davide Noto, Giuseppe Pirrone, Giuseppe Ambrosiano, Angelo B. Cefalù, Antonio Carroccio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalRecenti Progressi in Medicina
Volume97
Publication statusPublished - 2006

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of '[ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE'. Together they form a unique fingerprint.

Cite this